Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Fallopian Tube Neoplasms 16Ovarian Neoplasms 14Triple Negative Breast Neoplasms 9Lung Neoplasms 9Brenner Tumor 9Breast Neoplasms, Male 9Adenocarcinoma of Lung 9Adenocarcinoma, Bronchiolo-Alveolar 8Unspecified Adult Solid Tumor, Protocol Specific 7Endometrial Neoplasms 7Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 6Melanoma 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Esophageal Neoplasms 3Carcinoma, Transitional Cell 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2Platinum-Refractory Fallopian Tube Carcinoma 2Oropharyngeal Neoplasms 2Endometrial Adenocarcinoma 2Carcinoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Testicular Neoplasms 1Stomach Neoplasms 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9Cisplatin 6Biopsy 5Paclitaxel 4pembrolizumab 3Platinum 3Immunoglobulin G 3Disulfides 3Cetuximab 3Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3ipatasertib 2cemiplimab 2Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Radiation 2Docetaxel 2Cytoreduction Surgical Procedures 2Bevacizumab 2ALT-803 2peposertib 1peginterferon alfa-2b 1interferon gamma-1b 1fludarabine phosphate 1fludarabine 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Carcinoma × Taxes × Clear all
NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
180 enrolled
Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡